BILL · 2025–26 SESSION

HB 1725: Biosimilar medicines

Increasing access to biosimilar medicines.

Summary

Authorizes a pharmacist to substitute a biosimilar for a reference biologic product to the same extent as an interchangeable biological product.

From the House Bill Analysis 2025 (HB 1725), written by the Legislature's nonpartisan staff. Read the full report ↗

Did not pass Did not pass · died in committee

AN ACT Relating to reducing prescription drug costs by eliminating barriers impeding access to biosimilar medicines;

No recorded floor votes. This measure never reached a floor vote.

Bill numbers restart every two years, so the same number is a different bill in each session.

HB 1725 (2023–24) Insulin/access under 21 · Did not pass · died in committee
HB 1725 (2021–22) Missing indigenous persons · Enacted · Chapter 256, Laws of 2022
HB 1725 (2019–20) Pesticide application safety · Did not pass · passed House, stalled in Senate
HB 1725 (2017–18) Concealed pistol lic holders · Did not pass · died in committee
HB 1725 (2015–16) DSHS provider payment/hrs/wk · Enacted · Chapter 30, Laws of 2016, 1st Special Session
HB 1725 (2013–14) Tuition support fund program · Did not pass · died in committee
HB 1725 (2011–12) Workers' compensation · Enacted · Chapter 290, Laws of 2011
HB 1725 (2009–10) Small acreage timber harvest · Did not pass · died in committee